The global market for microRNA (miRNA) is estimated at US$346.2 Million in 2023 and is projected to reach US$919.2 Million by 2030, growing at a CAGR of 15.0% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the miRNA market is driven by several factors, including advances in miRNA profiling technologies, increased investment in miRNA research and therapeutic development, and a growing awareness of the potential of miRNAs in precision medicine. Technological advancements have led to more efficient and cost-effective methods for detecting and quantifying miRNAs, enhancing their applicability in both research and clinical settings. The pharmaceutical and biotechnological sectors are increasingly focusing on developing miRNA-based therapeutics, attracted by their ability to target multiple aspects of disease pathways. Moreover, as the healthcare industry moves toward more personalized treatment options, the demand for miRNA diagnostics and therapeutics is expected to rise, reflecting their potential to tailor treatments to individual genetic profiles and disease conditions. This trend is bolstered by a growing body of research that links specific miRNAs to particular diseases, further underpinning the clinical value of miRNAs as both biomarkers and therapeutic targets.
The growth in the miRNA market is driven by several factors, including advances in miRNA profiling technologies, increased investment in miRNA research and therapeutic development, and a growing awareness of the potential of miRNAs in precision medicine. Technological advancements have led to more efficient and cost-effective methods for detecting and quantifying miRNAs, enhancing their applicability in both research and clinical settings. The pharmaceutical and biotechnological sectors are increasingly focusing on developing miRNA-based therapeutics, attracted by their ability to target multiple aspects of disease pathways. Moreover, as the healthcare industry moves toward more personalized treatment options, the demand for miRNA diagnostics and therapeutics is expected to rise, reflecting their potential to tailor treatments to individual genetic profiles and disease conditions. This trend is bolstered by a growing body of research that links specific miRNAs to particular diseases, further underpinning the clinical value of miRNAs as both biomarkers and therapeutic targets.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the microRNA Products segment, which is expected to reach US$453.7 Million by 2030 with a CAGR of a 13.2%. The microRNA Services segment is also set to grow at 16.9% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $135.7 Million in 2023, and China, forecasted to grow at an impressive 18.7% CAGR to reach $99.9 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global microRNA (miRNA) Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global microRNA (miRNA) Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global microRNA (miRNA) Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Abcam PLC, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 64 Featured):
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Abcam PLC
- BioVendor - Laboratorni medicina a.s
- GeneCopoeia, Inc.
- AKESOgen, Inc.
- Entos Pharmaceuticals
- Genomnia
- Guangzhou Ruibo Biotechnology Co., Ltd.
- 20Med Therapeutics
- AceRNA Technologies Co., Ltd.
- AptamiR Therapeutics
- Causeway Therapeutics
- Cardior Pharmaceuticals
- Craif
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYREST OF EUROPEREST OF WORLDIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
Companies Mentioned
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Abcam PLC
- BioVendor - Laboratorni medicina a.s
- GeneCopoeia, Inc.
- AKESOgen, Inc.
- Entos Pharmaceuticals
- Genomnia
- Guangzhou Ruibo Biotechnology Co., Ltd.
- 20Med Therapeutics
- AceRNA Technologies Co., Ltd.
- AptamiR Therapeutics
- Causeway Therapeutics
- Cardior Pharmaceuticals
- Craif
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 379 |
| Published | December 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 346.2 Million |
| Forecasted Market Value ( USD | $ 919.2 Million |
| Compound Annual Growth Rate | 15.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
